Press Release

TRI® receives FDA 510 (k) clearance for matrix®, the world's first dental implant without an abutment for the full digital workflow

Switzerland, January 2022 – **TRI® Dental Implants today announced that the U.S. Food and Drug Administration (FDA) has cleared the matrix® implant system. The matrix® is the first-ever dental implant system approved for restorations directly on the implant without the use of an abutment.**

This unique implant concept has been designed for the digital workflow, eliminating the abutment. It allows for direct restorations from screw-retained full-anatomic CAD/CAM crowns to multi-unit bars and bridges which can be planned and placed directly on the implant. No limitation in angulation and indication, no need of cementation as well as the unique option to plan 100% patient-individual emergence profiles digitally guarantee longevity, high esthetic results and an unforeseen ease in handling.

TRI®'s vision of the future digital workflow

In the past years prosthetic manufacturing has completely changed and new materials were developed with new levels of precision. However, the implant interfaces have remained unchanged for the last 30-40 years, leading to a mismatch between implant connections and modern digital prosthetic manufacturing. The TRI® mission is to connect these two worlds and link it with the first digital implant solution: the matrix® implant system, a technology ahead of its time.

Sandro Venanzoni, Chief Technology Officer, stated "Within the fast changing dental implant market driven by digitalization, it was our goal to develop the first digital implant solution that eliminates the abutment and makes use of the high precision standards within digital prosthetic manufacturing to fabricate the final crown - whilst being fully embedded and compatible with all the leading digital scanners as well CAD and CAM software's in the market"

Peace of mind for the dental clinic

With the matrix® implant system dental clinics worldwide will embrace a new level of simplicity with unique benefits such as faster, easier, more predictable and cost-effective treatments - all available with local workflow (chairside and labside) milling as well as increased precision due to no abutment, no cement, no model, and no analog. The matrix® sets no limits in materials, indications, and angulations.

Tobias Richter, Founder and Chief Executive Officer, stated, "The FDA clearance for the matrix® implant system is a significant milestone for TRI®. This accomplishment will not only open new market opportunities, but is further strong confirmation for the design and high quality of the matrix® technology as a superior solution for the full

digital implant workflow. With the matrix®, patient treatments will be faster, more esthetic, closer to biology and easier than ever before - and therefore changing the life of the practitioner and patient for the better!""

Further information about the matrix® implant system can be found on the TRI® website www.tri.swiss.

About TRI® Dental Implants

TRI® Dental Implants is a fast-growing global provider for inspiring digital implant solutions. TRI® provides high-quality, innovative and easy-to-use implant solutions for the benefit of patients worldwide. The company is headquartered in Hünenberg, Switzerland. All products are designed and produced in the heart of Switzerland and distributed into more than 50 countries worldwide.

Contact:

TRI® Dental Implants Int. AG
Valentina Ciullo
Head of Global Marketing
Bösch 80A
CH-6631 Hünenberg
Switzerland
Phone: +41 32 510 1608
E-Mail: valentina.ciullo@tri-implants.swiss